A focused gastrointestinal review should ask about nausea, vomiting, abdominal distension, reflux, early satiety, constipation, postprandial fullness, and prior gastroparesis
The only rejection was emildeltide, also known as DSIP, or Deep Sleep Inducing Peptide, which failed 6-7
Other important safety considerations include the potential for hypoglycaemia, particularly in patients with diabetes taking concomitant glucose-lowering medications
These drugs are thought to dampen dopamine-driven reward signals, which help reduce the cravings for food and other compulsive behaviors
Technically yes, but its not recommended